SESEN BIO INC: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei SESEN BIO INC listata cu simbolul US.SESN ==Descriere companie== Sesen Bio, Inc. (https://sesenbio.com/) is a late-stage clinical company providing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. Its product pipeline includes Vicinium, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of BCG-unrespon...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Sesen Bio, Inc. (https://sesenbio.com/) is a late-stage clinical company providing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. Its product pipeline includes Vicinium, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. | Sesen Bio, Inc. (https://sesenbio.com/) is a late-stage clinical company providing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. Its product pipeline includes Vicinium, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant [[one]]-step, microbial manufacturing process. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 3 octombrie 2024 08:58
Pagina dedicata companiei SESEN BIO INC listata cu simbolul US.SESN
Descriere companie[edit | ]
Sesen Bio, Inc. (https://sesenbio.com/) is a late-stage clinical company providing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. Its product pipeline includes Vicinium, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process.
Grafic actiuni companie[edit | ]